Understand the source comparison
Thymalin Protocol vs Competing Immunomodulators: Mechanism Comparison
Thymalin Thymic peptide extract. T-lymphocyte differentiation via thymulin receptor activation Subcutaneous injection 2–3x weekly for 10–20 weeks Phase II Soviet-era trials, limited Western replication Strongest evidence for age-related thymic involution; requ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic peptide extract. T-lymphocyte differentiation via thymulin receptor activation
- Subcutaneous injection
- 2–3x weekly for 10–20 weeks
- Phase II Soviet-era trials, limited Western replication
- Strongest evidence for age-related thymic involution; requires reconstitution expertise
- Thymosin Alpha-1
- Synthetic 28-amino-acid peptide. Upregulates IL-2 and IFN-gamma via TLR pathways
- 1–2x weekly for 12–24 weeks
- Multiple Phase III trials in hepatitis/cancer contexts
- FDA-approved in 35+ countries (not US); more standardised than thymalin
- Beta-Glucan (oral)
- Polysaccharide. Macrophage activation via dectin-1 receptor
- Oral supplementation
- Daily
- Observational studies, no large RCTs
- Minimal absorption through GI tract; marginal systemic immune effect
- Astragalus Extract
- Multi-component botanical. Proposed telomerase activation
- In vitro data only; no human RCTs
- Unproven mechanism; contamination risk in unregulated products
- Thymalin occupies a distinct mechanistic position. It acts on thymic epithelial cells to support T-cell maturation rather than directly activating peripheral immune cells. This positions it for immune reconstitution contexts (post-chemotherapy, HIV-related thymic damage, aging-associated involution) rather than acute immune stimulation. The trade-off is preparation complexity and limited Western clinical validation compared to thymosin alpha-1.